Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

Cited In for PubMed (Select 21324516)

1.

Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.

Dodova RI, Mitkova AV, Dacheva DR, Hadjo LB, Vlahova AI, -Hadjieva MS, Valev SS, Caulevska MM, Popova SD, Popov IE, Dikov TI, Sedloev TA, Ionkov AS, Timcheva KV, Christova SL, Kremensky IM, Mitev VI, Kaneva RP.

BMC Cancer. 2015 Jul 17;15(1):523. doi: 10.1186/s12885-015-1516-2.

2.

Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.

Judkins T, Leclair B, Bowles K, Gutin N, Trost J, McCulloch J, Bhatnagar S, Murray A, Craft J, Wardell B, Bastian M, Mitchell J, Chen J, Tran T, Williams D, Potter J, Jammulapati S, Perry M, Morris B, Roa B, Timms K.

BMC Cancer. 2015 Apr 2;15:215. doi: 10.1186/s12885-015-1224-y.

3.

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.

Belanger MH, Dolman L, Arcand SL, Shen Z, Chong G, Mes-Masson AM, Provencher D, Tonin PN.

J Ovarian Res. 2015 Mar 27;8(1):1. doi: 10.1186/s13048-015-0124-8.

4.

Development of cancer genetic services in the UK: A national consultation.

Slade I, Riddell D, Turnbull C, Hanson H, Rahman N; MCG programme.

Genome Med. 2015 Feb 2;7(1):18. doi: 10.1186/s13073-015-0128-4. eCollection 2015.

5.

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.

Candido-dos-Reis FJ, Song H, Goode EL, Cunningham JM, Fridley BL, Larson MC, Alsop K, Dicks E, Harrington P, Ramus SJ, de Fazio A, Mitchell G, Fereday S, Bolton KL, Gourley C, Michie C, Karlan B, Lester J, Walsh C, Cass I, Olsson H, Gore M, Benitez JJ, Garcia MJ, Andrulis I, Mulligan AM, Glendon G, Blanco I, Lazaro C, Whittemore AS, McGuire V, Sieh W, Montagna M, Alducci E, Sadetzki S, Chetrit A, Kwong A, Kjaer SK, Jensen A, Høgdall E, Neuhausen S, Nussbaum R, Daly M, Greene MH, Mai PL, Loud JT, Moysich K, Toland AE, Lambrechts D, Ellis S, Frost D, Brenton JD, Tischkowitz M, Easton DF, Antoniou A, Chenevix-Trench G, Gayther SA, Bowtell D, Pharoah PD; for EMBRACE; kConFab Investigators; Australian Ovarian Cancer Study Group.

Clin Cancer Res. 2015 Feb 1;21(3):652-7. doi: 10.1158/1078-0432.CCR-14-2497. Epub 2014 Nov 14.

6.

BRCA-associated ovarian cancer: from molecular genetics to risk management.

Girolimetti G, Perrone AM, Santini D, Barbieri E, Guerra F, Ferrari S, Zamagni C, De Iaco P, Gasparre G, Turchetti D.

Biomed Res Int. 2014;2014:787143. doi: 10.1155/2014/787143. Epub 2014 Jul 22. Review.

7.

BRCA1 founder mutations compared to ovarian cancer in Belarus.

Savanevich A, Oszurek O, Lubiński J, Cybulski C, Dębniak T, Narod SA, Gronwald J.

Fam Cancer. 2014 Sep;13(3):445-7. doi: 10.1007/s10689-014-9721-8.

8.

The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population.

Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, Fridley BL, Tyrer JP, Alsop J, Jimenez-Linan M, Gayther SA, Goode EL, Pharoah PD.

Hum Mol Genet. 2014 Sep 1;23(17):4703-9. doi: 10.1093/hmg/ddu172. Epub 2014 Apr 12.

9.

BRCA and Early Events in the Development of Serous Ovarian Cancer.

George SH, Shaw P.

Front Oncol. 2014 Jan 23;4:5. doi: 10.3389/fonc.2014.00005. eCollection 2014. Review.

10.

Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status.

Nilsson MP, Hartman L, Idvall I, Kristoffersson U, Johannsson OT, Loman N.

Breast Cancer Res Treat. 2014 Feb;144(1):133-42. doi: 10.1007/s10549-014-2842-9. Epub 2014 Jan 30.

11.

Gene-gene interaction network analysis of ovarian cancer using TCGA data.

Ying H, Lv J, Ying T, Jin S, Shao J, Wang L, Xu H, Yuan B, Yang Q.

J Ovarian Res. 2013 Dec 6;6(1):88. doi: 10.1186/1757-2215-6-88. Retraction in: J Ovarian Res. 2015;8(1):18. J Ovarian Res. 2015;8:18. doi:10.1186/s13048-015-0146-2.

12.

Outcomes of screening endometrial cancer patients for Lynch syndrome by patient-administered checklist.

Daniels MS, Urbauer DL, Zangeneh A, Batte BA, Dempsey KM, Lu KH.

Gynecol Oncol. 2013 Dec;131(3):619-23. doi: 10.1016/j.ygyno.2013.10.011. Epub 2013 Oct 17.

13.

BRCA sequencing and large rearrangement testing in young Black women with breast cancer.

Pal T, Bonner D, Cragun D, Johnson S, Akbari M, Servais L, Narod S, Vadaparampil S.

J Community Genet. 2014 Apr;5(2):157-65. doi: 10.1007/s12687-013-0166-9. Epub 2013 Aug 29.

14.

Risk factors for ovarian cancers with and without microsatellite instability.

Segev Y, Pal T, Rosen B, McLaughlin JR, Sellers TA, Risch HA, Zhang S, Ping S, Narod SA, Schildkraut J.

Int J Gynecol Cancer. 2013 Jul;23(6):1010-5. doi: 10.1097/IGC.0b013e31829a5527. Retraction in: Beller U. Int J Gynecol Cancer. 2014 Sep;24(7):1356.

15.

Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases.

Stavropoulou AV, Fostira F, Pertesi M, Tsitlaidou M, Voutsinas GE, Triantafyllidou O, Bamias A, Dimopoulos MA, Timotheadou E, Pectasides D, Christodoulou C, Klouvas G, Papadimitriou C, Makatsoris T, Pentheroudakis G, Aravantinos G, Karydakis V, Yannoukakos D, Fountzilas G, Konstantopoulou I.

PLoS One. 2013;8(3):e58182. doi: 10.1371/journal.pone.0058182. Epub 2013 Mar 11. Erratum in: PLoS One. 2013;8(4). doi:10.1371/annotation/159f0ba3-5a24-4de9-99be-1cd6d5037760.

16.

Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient.

Zhang J, Shi Y, Lalonde E, Li L, Cavallone L, Ferenczy A, Gotlieb WH, Foulkes WD, Majewski J.

BMC Cancer. 2013 Mar 22;13:146. doi: 10.1186/1471-2407-13-146.

17.

Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer.

Thompson ER, Rowley SM, Sawyer S, kConfab, Eccles DM, Trainer AH, Mitchell G, James PA, Campbell IG.

PLoS One. 2013;8(1):e54772. doi: 10.1371/journal.pone.0054772. Epub 2013 Jan 25.

18.

Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing.

Norquist BM, Pennington KP, Agnew KJ, Harrell MI, Pennil CC, Lee MK, Casadei S, Thornton AM, Garcia RL, Walsh T, Swisher EM.

Gynecol Oncol. 2013 Mar;128(3):483-7. doi: 10.1016/j.ygyno.2012.12.015. Epub 2012 Dec 19.

19.

Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.

McLaughlin JR, Rosen B, Moody J, Pal T, Fan I, Shaw PA, Risch HA, Sellers TA, Sun P, Narod SA.

J Natl Cancer Inst. 2013 Jan 16;105(2):141-8. doi: 10.1093/jnci/djs494. Epub 2012 Dec 20.

20.

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G.

J Clin Oncol. 2012 Jul 20;30(21):2654-63. doi: 10.1200/JCO.2011.39.8545. Epub 2012 Jun 18. Erratum in: J Clin Oncol. 2012 Nov 20;30(33):4180.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk